@avarive09
So you've read up hey?
LNA043 is an unproven protein therapy that has P2 clinical trials set to run for 5 years (late 2027)
Whilst admirable, cartilage repair via still unknown MOA has many additional hurdles to overcome. Moreover, it's really only attacking one piece of the OA puzzle.
Remember PAR's Zilosul only needs 10% US OA market traction to get to CSL annual revenue. So plenty of room for competition when and if it arrives.
I terms of much bigger company and resources comment. All the top 15 biopharma groups by revenue all sponsor specific OA research. Wonder which ones PAR is currently talking to is perhaps the more pertinent question??????
- Forums
- ASX - By Stock
- PAR
- Ann: Investor Presentation - $66m Capital Raise
Ann: Investor Presentation - $66m Capital Raise, page-64
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
29.8¢ |
Change
0.003(0.85%) |
Mkt cap ! $103.1M |
Open | High | Low | Value | Volume |
30.0¢ | 30.0¢ | 29.5¢ | $34.53K | 115.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 40539 | 29.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
28.5¢ | 56 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 40539 | 0.295 |
5 | 27379 | 0.290 |
3 | 52806 | 0.285 |
1 | 50000 | 0.280 |
1 | 5000 | 0.275 |
Price($) | Vol. | No. |
---|---|---|
0.285 | 56 | 1 |
0.305 | 10000 | 1 |
0.310 | 80900 | 3 |
0.315 | 58007 | 5 |
0.320 | 120187 | 5 |
Last trade - 15.59pm 22/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |